Milestone Pharmaceuticals Inc. (MIST) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.72 (-1.22% 1D, market cap $89.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MIST ranks #690 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIST carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GNLX (Genelux Corporation) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $90.5M) and RTSN (Retension Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $89.1M). Among the 5-stock peer group, MIST leads on earnings multiple (N/A) while MIST leads on capital efficiency (-35.0% ROIC).
Per MIST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001408443), Milestone Pharmaceuticals Inc. generated $174.0M in revenue (+47.6% YoY), -$63.1K in net income, and -$49.3M in free cash flow against $113.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Capital intensity & 0% operating margin leave 16 pts on the table
While MIST currently carries a cautious 33/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.87) and Max Pain ($0.76) forces dealer call-delta covering toward $3.21.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Milestone Pharmaceuticals Inc. (MIST) slipped -1.22% to $0.72, trading at 4% of its 52-week range ($0.63 – $3.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular me
MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular me
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +47.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MIST today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MIST. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Milestone Pharmaceuticals Inc. (MIST) ranks #690 by composite RQD confidence (33/100, grade E) and #665 by equity capitalization ($89.8M). Within this direct 5-issuer industry benchmark cohort, MIST leads on earnings valuation at N/A trailing P/E, while MIST leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with MIST at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MIST
ACTIVE
Milestone Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | -1.22% | $89.8M | Benchmark Subject |
| GNLX Genelux Corporation | E | 26/100 | — | — | -35.0% | -3.85% | $90.5M | /gnlx-vs-mist → |
| RTSN Retension Pharmaceuticals Inc. | D | 51/100 | — | — | — | -0.53% | $89.1M | /rtsn-vs-mist → |
| TNXP Tonix Pharmaceuticals Holding Corp. | E | 25/100 | — | 49.3% | -35.0% | +0.98% | $88.3M | /tnxp-vs-mist → |
| NTHI NeOnc Technologies Holdings Inc. | E | 31/100 | — | — | -35.0% | -5.83% | $91.4M | /nthi-vs-mist → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Pharmaceuticals Inc. (MIST) reported GAAP revenue of $174.0M (+47.6% vs. FY2024 revenue of $117.9M , and +1.7% cumulative change since FY2023) , GAAP net income of -$63.1K, operating cash flow of -$49.0M, and free cash flow of -$49.3M (-70.8% YoY). On the balance sheet, MIST closed FY2025 with $113.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $174.0M | -$63.1K | -$49.0M | -$49.3M | $113.6M | — |
| FY2024 (FY) | 2024-12-31 | $117.9M | -$41.5K | -$28.8M | -$28.9M | $75.5M | — |
| FY2023 (FY) | 2023-12-31 | $171.1M | -$59.7K | -$46.4M | -$46.4M | — | — |
As of 2026-11-03, Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.72 (-1.22% 1D, market cap $89.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MIST ranks #690 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIST carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GNLX (Genelux Corporation) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $90.5M) and RTSN (Retension Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $89.1M). Among the 5-stock peer group, MIST leads on earnings multiple (N/A) while MIST leads on capital efficiency (-35.0% ROIC).
Per MIST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001408443), Milestone Pharmaceuticals Inc. generated $174.0M in revenue (+47.6% YoY), -$63.1K in net income, and -$49.3M in free cash flow against $113.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
MIST last traded at $0.72 (-1.22% on volume of 748,839 shares), positioning the stock -17.24% below its 50-day simple moving average ($0.87) and -46.67% below its 200-day simple moving average ($1.35). Across its 52-week range of $0.63 to $3.06, MIST sits at the 3.7% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).
Milestone Pharmaceuticals Inc. (MIST) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.72 (-1.22% 1D, market capitalization $89.8M).
Milestone Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Reported revenue is — in each of the three periods shown, indicating no revenue recognition in the reported data. Market capitalization is $0.1B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Milestone Pharmaceuticals Inc. (MIST) reported $174.0M in annual revenue (up from $117.9M in FY2024, +47.6% YoY) and -$63.1K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($171.1M revenue, -$59.7K net income) through FY2025, MIST scaled operating cash flow to -$49.0M and free cash flow to -$49.3M, backed by $113.6M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MIST carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Milestone Pharmaceuticals Inc. (MIST) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Institutional accumulation and options positioning score 15 of 20, and a GREEN clinical enrollment item signals some pipeline progress.. When you look under the hood at MIST, Fundamental Cash Engine is 4/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $3.06. My 12M target is $0.93.
@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Here is the bear case nobody on the bull side wants to address on MIST: ROIC of -35%, FCF of -$49.3M in FY 2025, and a Piotroski F-Score of 1/9 combine with active Nasdaq listing-compliance issues.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: